MicroRNAs in nasopharyngeal carcinoma.
It is becoming increasingly evident that aberrantly expressed microRNAs (miRNAs) are responsible for a number of disease processes, including cancer initiation and progression. miRNAs have been implicated as key players in numerous neoplasms, including nasopharyngeal carcinoma (NPC). Functionally, deregulation of miRNAs that act either as tumour suppressors or oncogenes results in numerous cancer-associated phenomena, including changes in proliferation, migration, and cell survival. Furthermore, miRNA expression has been associated with chemoresistant or radioresistant phenotypes; highlighting the importance of miRNAs in mediating oncogenic processes. Prognostic and predictive miRNA signatures have been defined for a variety of cancer types, including NPC, whereby these signatures offer a potentially important clinical tool for assessing the disease state, as well as predicting treatment response and clinical outcome. Therefore, further examination and validation of miRNAs that are deregulated in NPC will provide insight into the fundamental drivers of this disease, which will aid in the identification of novel targeted treatments. This review summarizes recent advances in the study of miRNAs in NPC, with specific discussion on the role of miRNAs in NPC pathogenesis and the potential utility of miRNAs as prognostic biomarkers. Our increasing understanding of the role of miRNAs in NPC tumorigenesis and their application as novel biomarkers will undoubtedly prove useful in the stratification of future patients into clinically relevant treatment classifications, thereby improving and personalizing disease management.
Department of Radiation Oncology, Princess Margaret Cancer Centre, UHN, Toronto, Ontario, Canada.
Tara
T
Spence
Department of Radiation Oncology, Princess Margaret Cancer Centre, UHN, Toronto, Ontario, Canada.
Jeff
J
Bruce
Department of Radiation Oncology, Princess Margaret Cancer Centre, UHN, Toronto, Ontario, Canada.
Kenneth W
KW
Yip
Department of Radiation Oncology, Princess Margaret Cancer Centre, UHN, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada. Fei-Fei.Liu@rmp.uhn.on.ca.
Fei-Fei
FF
Liu
D014408:Biomarkers, Tumor / Q000235:genetics*; D002277:Carcinoma; D015972:Gene Expression Regulation, Neoplastic; D016147:Genes, Tumor Suppressor; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000472:pathogenicity; D006801:Humans; D035683:MicroRNAs; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000235:genetics* / Q000473:pathology / Q000821:virology; D011379:Prognosis; D058727:RNA, Small Untranslated
D014408:Biomarkers, Tumor; D035683:MicroRNAs; D058727:RNA, Small Untranslated
Epstein-Barr virus-miRNAs; MicroRNA (miRNA); nasopharyngeal carcinoma (NPC); prognostic biomarker